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Taking  into  consideration  renal  hyperten-
sion-induced  homeostatic  disorders  and  the
key  role  of  calcitonin  gene-related  peptide
(CGRP) in many, systemic functions regulat-
ing systems, a question arises as to what an
extent arterial hypertension affects the mor-
phology  and  dynamics  of  pulmonary  CGRP-
immunopositive cell changes. The aim of the
present study was to examine the distribution,
morphology and dynamics of changes of CGRP-
containing cells in the lungs of rats in the two-
kidney,  one-clip  (2K1C)  renovascular  hyper-
tension model. The studies were carried out on
the lungs of rats after 3, 14, 28, 42, and 91 days
long period from the renal artery clipping pro-
cedure.  In  order  to  identify  neuroendocrine
cells, immunohistochemical reaction was per-
formed  with  the  use  of  a  specific  antibody
against CGRP. It was revealed that renovascu-
lar hypertension caused changes in the neu-
roendocrine,  CGRP-containing  cells  in  the
lungs  of  rats.  The  changes,  observed  in  the
neuroendocrine cells, depended on time peri-
ods  from  experimentally  induced  hyperten-
sion. The highest intensity of changes in the
neuroendocrine  cells  was  observed  in  the
lungs of rats after 14 days from the surgery.
Introduction
Arterial hypertension results in ischemia of
tissues and organic insufficiency, the process,
occurring  at  both  systemic  and  local  levels.
Hypertension leads to disorders of many sys-
tems and organs, causing cardiac hypertrophy,
increased  sclerosis  development,  metabolic
disorders,  anaemia  and  neurological  distur-
bances, while local changes affect, first, vascu-
lar  walls.1,2 Endothelial  dysfunction  is
observed,  as  well  as  activation  of  mitogenic
factors, leading to hypertrophy of tunica intima
and  vascular  media3-5 and  the  production  of
aerobic  radicals  and  prostaglandins  is
increased.6
The maintenance of arterial blood pressure
within normal values is a significant link for
the  homeostatis  controlling  mechanisms,7
involving the nervous system, the kidneys, the
hormonal system and many other factors, sig-
nificantly controlling the motor activity of vas-
cular  walls  building  smooth  muscle  cells.8-10
Arterial hypertension develops from disorders
in arterial blood pressure controlling mecha-
nisms  and  from  a  disturbed  relationship
between vasodilative and vasoconstrictive fac-
tors.11
Regarding  the  pathogenesis  of  arterial
hypertension, experimental studies prove a big
role  of  the  neuropeptides,  secreted  by  neu-
roendocrine cells of the epithelium in the air-
ways, the gastrointestinal tract and in the gen-
itourinary tract.12-18 The calcitonin gene-relat-
ed peptide (CGRP) is one of the substances,
fairly significant for hypertension aetiology.19,20
CGRP participates in a number of physiological
and pathological processes, including inflam-
matory processes, suppression of cell prolifer-
ation and cardiovascular control.21CGRP is one
of the strongest vasodilators, increasing blood
flow rates in cerebral and coronary vessels, as
well as in cutaneous vessels,22 exerting posi-
tive  chronotropic  and  inotropic  effects.23
CGRP-containing,  afferent,  sensory  nerve
fibres innervate blood vessel walls.24 CGRP is
also  localised  in  vascular  endothelium.25
Afferent pulsation causes CGRP release from
nerve  endings,  contributing  to  vasodilative
effects,26 while  both  forms  of  CGRP,  i.e.,  a-
CGRP and b-CGRP are for this process respon-
sible.27
It appears from reports of many authors that
CGRP plays a significant role in the initiation
and  progression  of  hypertension.22,27 It  has
been demonstrated that CGRP plays a protec-
tive  function  for  endothelial  cells  and  for
smooth muscle cells.28,29 It decreases muscular
layer  tension,  binding  with  an  appropriate
receptor or enhancing nitrogen oxide synthe-
sis.30 Moreover, it exerts antagonistic effects
on  the  renin-angiotensin-aldosterone  (RAA)
system and endothelins, demonstrating cardio-
protective properties.31 Therefore, it has been
assumed that CGRP plays an important role in
blood  pressure  modulation  in  physiological
conditions, as well as in the pathophysiology of
hypertension.
CGRP is one of the peptides, secreted by the,
so-called-  pulmonary  neuroendocrine  cells
(PNEC),  which  occur  individually  in  airway
epithelium as neuroepithelial bodies (NEB).32
It appears from a literature review that, in var-
ious pathological situations, both the number
and morphology of these cells undergo certain
changes, what lets assume their active partici-
pation in many processes.32-35
No data were found in the available litera-
ture,  concerning  CGRP-positive  pulmonary
cells in systemic hypertension of various aeti-
ology.  Taking  into  account  that  fact,  it  was
decided to evaluate the dynamics of changes in
the numbers of CGRP-positive pulmonary cells
in rats with renovascular hypertension.
Materials and Methods
Experimental animals
All the procedures involving the animals and
their care were conducted in conformity with
the institutional guidelines that are in compli-
ance with national and international law and
with guidelines for the use of animals in bio-
medical research.36
Study assumptions, aim, schedule and mode
of  animal  treatment  were  approved  by  the
Senate  Committee  for  Supervision  of
Experiments on Humans and Animals, Medical
University of Bialystok, Poland.
The study was performed on fifty (50) young
male  Wistar  rats,  their  body  weight  at  the
beginning of the experiment remaining within
160-180 g (mean body weight: 170±10 g). The
rats were housed in lighted and ventilated con-
ditions  with  room  temperature  and  regular
day/night  rhythm.  The  animals  had  a  free
access to standard granulated chow and drink-
ing  water  was  available  ad  libitum.  All  the
experiments were performed at the same time
of the day.
After 1 week of acclimatization, the systolic
blood pressure (SBP) was measured in each
rat was measured and the renovascular hyper-
tension inducing procedure was performed.
Two-kidney, one-clip renovascular
hypertension
After the rats were anesthetized by exposure
to  pentobarbital  (40  mg/kg,  i.p.),  a  3-cm
retroperitoneal flank incision was performed
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under sterile conditions. The left kidney was
exposed and the renal artery was carefully dis-
sected free of the renal vein. The renal artery
was then partially occluded by placing a silver
clip with an internal diameter of 0.20 mm on
the vessel. The wound was closed with a run-
ning 3-0 silk suture (n=30). Sham operated
rats (n=20) had identical surgery except artery
clipping. 
Histology
Method of experimental material collection
and fixation
After 3, 14, 28, 42 and 91 days from the renal
artery clipping procedure, the rats (six exam-
ined  and  four  controls)  were  anaesthetized
with pentobarbital (50 mg/kg b.w.) and sacri-
ficed by decapitation. Following thoracotomy,
the lungs were collected in whole. Immediately
after the preparation of the collected organs,
Bouin’s fluid was administered by syringe into
the trachea to smooth the pulmonary pleura in
the right lung. Following the trachea ligation,
the lung was fixed in Bouin’s fluid for 24 h at
4°C. Then, following lobectomy from circum-
ference to the hilus, the anterior part of the
superior pulmonary lobe was routinely placed
in  paraffin  blocks  and  then  sectioned  by  a
Leica 2025 rotating microtome. The paraffin
blocks  were  cut  into  4  mm  sections  and
attached to positively charged glass slides.
Identification of endocrine cells by
immunohistochemical methods
In  the  immunohistochemical  study,  the
EnVision  method  was  used,  according  to
Herman and Elfont.37 An immunohistochemi-
cal reaction was run on the paraffin lung sec-
tions of the studied animals, searching for the
calcitonin  gene-related  peptide  in  neuroen-
docrine cells. In those studies, a specific anti-
body  against  CGRP  was  applied  (Cat.  No  C
8198, in 1:8000 dilution, Sigma-Aldrich, Saint
Louis, MO, USA). The antiserum was diluted
in  an  antibody  diluent  (S  0809,  Dako
Cytomation, Glostrup, Denmark). 
Immunohistochemical reaction procedure
Paraffin-embedded  sections  were  deparaf-
finized and hydrated in pure alcohols, then pre-
treated in a pressure chamber, heating for 1
min  at  21  psi  at  125ºC  with  S  2369  target
retrieval solution citrate of pH 6.0 (Dako) for
antigen retrieval. After cooling to room temper-
ature, the sections were incubated with S 2001
peroxidase blocking reagent (Dako) for 10 min
to block endogenous peroxidase activity. The
sections were incubated overnight at 4ºC in a
humidified chamber with the diluted antibody.
The antibody binding was visualized with sup-
port of an EnVision Kit (K 4011, Dako) with
labelled  polymer-HRP  anti-rabbit.  The  bound
antibodies were visualized by 1-min incubation
with  liquid  3,3’-diaminobenzidine  substrate
chromogen. The sections were finally counter-
stained in Vector QS haematoxylin, mounted
and  evaluated  under  light  microscope.
Appropriate washing with Wash Buffer S 3006
(Dako) was performed between each step. The
specificity tests, performed for the CGRP anti-
body,  included:  negative  control,  where  the
antibodies  were  replaced  by  normal  rabbit
serum (Vector Laboratories, Burlingame, CA,
USA)  at  the  respective  dilution  and  positive
control was obtained for specific tissue as rec-
ommended  by  the  producer  for  CGRP  is  rat
brain.  The  obtained  results  of  immunohisto-
chemical staining were submitted for evalua-
tion in an Olympus Bx50 microscope. Cells with
CGRP expression were searched for and their
topography was observed.
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Figure 1. Single cell containing CGRP in the lung of control rat. Scale bar: 100 µm.
Figure 2. Small few-cell clusters of NE cells with CGRP expression in rat lungs after three




tics of neuroendocrine cells in the
lung structures of control and two-
kidney, one-clip rats
Following immunohistochemical reactions,
the  neuroendocrine  (NE)  cells  were  clearly
distinguishable in structures of the analysed
organs of all the studied rats. The NE cells, sur-
rounded by other cells of the respiratory tract
epithelium, were distinct by dye and shape, the
latter  ranging  from  pyramidal  to  polygonal,
oval or columnar. In the lungs of the control
rats, CGRP-immunopositive cells occurred in
the respiratory tract as scattered, single or as
intraepithelial, small groups (most often 2-3
cells  only).  The  highest  number  of  NE  cells
with positive reaction to the antibodies against
CGRP was observed in larger bronchia, while
the  smallest  PNE  cell  numbers  occurred  in
alveolar  ducts  and  alveoli.  The  intensity  of
immunohistochemical  reaction  to  anti-CGRP
antibodies was moderate in the PNEC of con-
trol rats (Figure 1). 
After  three  days  from  artery  clipping,  the
number and localization of CGRP-immunore-
active cells in the lungs of the rats were simi-
lar to their control counterparts. A higher num-
ber of NE cells, grouped in small, few-cell clus-
ters of PNEC, was the only visible difference.
The  intensity  of  immunohistochemical  reac-
tion was also similar to that observed in the
control rats (Figure 2).
Two weeks after the left renal artery clip-
ping, clearly higher numbers of cells with pos-
itive  reaction  to  anti-CGRP  antibodies  were
found in the rats with experimentally induced
hypertension  vs.  control  animals.  Single  NE
cells, as well as NEBs, were localised at various
levels of the respiratory tracts of studied rats.
The most numerous NE cells, observed in
the  epithelium  of  bronchi,  where  CGRP-
immunopositive cells, frequently grouped into
large,  multicellular  clusters  of  PNE  cells.
Higher  numbers  of  CGRP-immunopositive
cells were also found in the lungs of rats in
that group vs. the other groups. Some CGRP-
immunopositive cells were also found at the
level of the alveolar ducts and of the alveoli
(Figure 3 A,B).
The  strongest  immunoreactivity  of  PNE
cells, both single and in small clusters, as well
as in large NEBs, was observed after 2 weeks
from the clipping procedure. After 28 days from
clipping, the number of NE cells with CGRP-
immunopositive reaction was slightly smaller
in the studied lungs, comparing to that in the
previous group animals. Cells with a positive
reaction  to  the  anti-CGRP  antibodies  were
found in the respiratory tract, most often as
scattered, single NE cells or in small, several-
cell clusters of NE cells (Figure 4). NEBs, with
higher numbers of NE cells, were identified
only sometimes and with a weaker expression
of CGRP, when compared to the previous ani-
mal group. 
The  number  and  localisation  of  CGRP-
immunoreactive cells in the lungs of the rats
after 42 and 91 days from the left renal artery
clipping were similar and comparable to those
in the animals after three days from clipping.
Most of the CGRP-immunopositive cells, which
were observed in the respiratory tract, includ-
ed  single  NE  cells,  while  small,  several-cell
clusters  of  PNE  cells  were  observed  in  the
bronchia and bronchioli of rats in those exper-
imental groups (Figure 5). The immunoreac-
tivity of PNE cells, both single and clustered,
was rather moderate. 
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Figure 3. A) Multicellular clusters of PNE cells with strong CGRP expression in the cyto-
plasm; scale bar: 100 µm. B) Rat lungs after 14 days from the left renal artery clipping;
scale bar: 50 µm. 
A
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Discussion
Topographic distribution and the occurrence
of CGRP-immunoreactive endocrine cells were
studied in lungs of hypertensive rats.
The pathogenesis of arterial hypertension is
complex  and  multifactorial  in  character.
Arterial blood pressure control is a very com-
plex process, involving various organs and sys-
tems: the kidneys with the RAA system, the
neurohormonal  system  with  participation  of
catecholamines, vasopressins and the nervous
system.4,10,38 There is strong interdependence
and  a  mutual  linkage  among  many  mecha-
nisms and blood pressure controlling factors.
Despite the big progress, which, so far, can be
perceived  in  the  pathophysiology  of  arterial
hypertension, it is still not known, which of
these factors play a decisive role in hyperten-
sion formation and development.
Arterial hypertension rarely occurs as isolat-
ed condition. In many cases, hypertension is
accompanied  by  medical  conditions,  which
are,  most  often,  its  complications.  It  seems
that, from the clinical point of view, the most
significant complications are those that cause
certain changes in the cardiovascular system.
Neuropeptides, like CGRP, play an integral role
in the pathophysiology of hypertension. CGRP
participates in the regulation of vascular tone
and  regional  organ  blood  flow,  what  was
demonstrated in many experimental data, as
well as observed in a number of clinical stud-
ies.20,21,39-41
CGRP-containing  nervous  fibers  are
localised on the borderline between the tunica
adventitia and media myocytes. CGRP recep-
tors are widely distributed in the cardiovascu-
lar system.42 For this reason, CGRP receptors
constitute a powerful effector system for the
regulation of vascular tone and regional blood
flow. It appears from studies of many authors
that both CGRP and/or CGRP receptor expres-
sion increase in hypertension.38,40 A blockade
of  CGRP  receptors  in  various  experimental
models caused an evident increase of arterial
hypertension.38,43
Potassium and calcium ions play a meaning-
ful role in the pathology of hypertension. ATP
(K  ATP)-dependent  potassium  channels  are
observed in endothelial cells and smooth mus-
cle cells of vessels, the channels being a com-
ponent of tonic vasorelaxation in general and
local circulation. Potassium channels are the
main  cell  membrane  potential  determining
elements and, in consequence, they take part
in  vascular  wall  tension  control.  Potassium
channel opening by factors, released from the
endothelium, e.g., nitrogen oxide (NO), prosta-
cyclin (PGI2), leads to flows of potassium ions
outwards  from  the  cell  inside,  resulting  in
hyperpolarisation, closure of potential-depend-
ent membranous calcium channels and dila-
tion of blood vessels. In turn, potassium chan-
nel  closure  with  calcium  channel  opening,
leads  to  depolarisation  and  contraction.44
Disturbed functions of potassium channels are
at the base of hypertension pathogenesis. The
potassium  channels,  which  selectively  filter
potassium  ions,  exert  their  effects  on  the
membranous potential of smooth muscle cells.
CGRP  stimulates  these  channels,  leading  to
hyperpolarisation of the membranes of vascu-
lar smooth muscle cells.45
The  results  of  our  earlier  studies  demon-
strate that experimentally induced renovascu-
lar hypertension in rats exerts a huge effect on
CGRP-positive  cells  in  the  lungs.  A  clear
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Figure 4. CGRP immunolabelling in the cytoplasm of NE cells (dark-colored granules) in
the lung of 2K1C rat after 28 days from clipping. Scale bar: 100 µm.
Figure 5. CGRP-immunopositive cells in the lung of 2K1C rat after 42 days from clip-
ping. Scale bar: 100 µm.[European Journal of Histochemistry 2012; 56:e10] [page 53]
increase in the number of CGRP-immunoreac-
tive cells was observed in the studied animals,
the cells being either single or clustered into
neuroepithelial bodies in various sections of
the  airways.  A  considerable  increase  in  the
number of those cells was found after 14 days
of  hypertension.  Then,  after  28  subsequent
days, the number of CGRP-positive cells was
minimally lower than in the animals after the
two-week duration of the experiment. While
after 42 and 91 days from the study, the ani-
mals  demonstrated  decreased  numbers  of
those cells, down to the level observed in the
lungs of the animals on the third day of the
hypertensive period. 
Hyperplasia of CGRP-immunoreactive cells
was  noted  in  neonatal  rats  with  congenital
diaphragmatic  hernia,46 carcinoid  tumours32
and in cigarette smokers.47 It was previously
stated that the production and release of neu-
ropeptides could significantly be altered in sev-
eral models of experimental hypertension.48-50
No data were found in the available literature
concerning the increasing number of airway
CGRP-containing neuroendocrine cells in the
conditions  of  renovascular  hypertension.
Therefore, it is rather difficult to explain the
cause of the increasing quantity of pulmonary,
CGRP-immunoreactive  cells,  as  observed  in
hypertension.
Stenosis of the renal artery mobilises the
RAA  system.  An  ischaemic  kidney  produces
excessive  renin  volumes,  that  consequently
results in an increased secretion of pressively
and  mitogenically  acting  angiotensin  II.5 An
increased blood pressure causes reduced oxide
supplementation to the lungs, while impairing
the gas exchange. Additionally, hypoxia signif-
icantly leads to contraction of pulmonary blood
vessels. Chronic oxygen deficiency increases
the number of neuroendocrine cells in the air-
ways.15,51 It  is  confirmed  by  Keith’s  studies,
who,  in  conditions  of  one-day  hypoxia,
observed hyperplasia of cells with 5-HT expres-
sion in rat foetuses. CGRP dilates pulmonary
blood vessels, reducing the effect of chronic
hypoxia.52 The role of CGRP in hypertension is
not  clear.  CGRP  administration  decreases
blood  pressure  both  in  animals  and  in  peo-
ple.23,50 Clinical studies have indicated that, in
patients with systemic hypertension, the levels
of  circulating  CGRP  may  be  decreased,
increased or unchanged,22,53 while in hyperten-
sive rats, the level of CGRP increases both in
vivo and in vitro conditions.50,54
In hypertension, regardless of its aetiology,
it comes to remodelling of blood vessels; these
changes include hyperplasia of the muscular
coat, fibrosis involves the tunica intima and
the  tunica  adventitia,  what  results  in
increased peripheral resistance.55 Cogo et al.
found  muscularisation  of  pulmonary  vessels
and proliferation of fibroblasts in various oxy-
gen conditions.56 In hypertensive lungs of the
experimental  animals,  thickened  vascular
media was observed, as well as big amounts of
connective tissue, both in tunica intima and
tunica adventitia. The observed morphological
changes  were  accompanied  by  an  increased
number of single CGRP-positive cells and of
neuroepithelial bodies, as well as by hyperpla-
sia  of  NEBs,  especially  after  two  weeks  of
hypertension. However, it is still an open ques-
tion why the cells increase in their numbers in
the lungs of animals with renovascular hyper-
tension.
The mean half-life of CGRP in plasma is rel-
atively short, amounting to approximately 10
min, then it undergoes inactivation with the
participation  of  tryptase  and  chymotrypsin.57
Therefore, it should be supposed that PNEC
hyperplasia, which was found in those studies,
is a CGRP deficit compensation mechanism.
The  lungs  in  physiological  and  pathological
conditions  are  subject  of  complex  control
processes, in which nervous and hormonal fac-
tors play a significant role, tailoring their func-
tions to the actual load of the system. There
are also local control mechanisms, which inte-
grate  the  elements  of  the  airway  functions,
including, by all means, the peptide, associat-
ed with calcitonin gene, i.e., CGRP. There are
many  factors  responsible  for  the  control  of
CGRP  expression  and  release.  Locally  pro-
duced  factors,  such  as  bradykinin  and
prostaglandins,58,59 endothelin and the sympa-
thetic nervous system,58 as well as the nerve
growth factor (NGF) reveal high physiological
significance in pulmonary flow control.60,61 It
has been shown that NGF is a stimulant of
CGRP mRNA synthesis. NGF would decrease
blood  pressure  through  the  stimulation  of
CGRP synthesis and release.61 The study sug-
gested  that  bradykinin  effects  resulted  from
the  cyclo-oxygenase  mediated  increase  in
prostaglandin production.59 It may be assumed
that those relationships can be the cause or
one of the causes of CGRP release.6,62 Probably,
these factors alter acute releases of CGRP and
can also modulate long-term production of this
peptide.
An increased number of CGRP immunoposi-
tive cells may be a consequence of disturbed
secretion of the peptide, what has been con-
firmed  by  Gosney’s  studies.46 He  found  an
increased  quantity  of  CGRP-positive  cells  in
rats with nitrofen-induced diaphragmatic her-
nia,  which  was  an  effect  of  the  suppressed
release of the peptide; which, in turn, predis-
poses to hypertension development, character-
istic for this disease.
A number of pathological pulmonary condi-
tions are accompanied by PNEC hyperplasia,
which  may  result  either  from  their  mitotic
divisions or from post-mitotic differentiation
of non-endocrine cells;63,64 however, this prob-
lem has still been awaiting its final solution.
Antihypertensive effects of CGRP may result
from the activation of neuroendocrine cells to
synthesis  and  release  of  this  neuropeptide
and/or from an increased sensitivity of the ves-
sels to CGRP activity.20,27
Hypertension-induced end organ damage is
one of the most severe and common conse-
quences  of  increased  blood  pressure.  Since
CGRP has such potent biological effects on the
lung suggesting that peptide is an endogenous
organ-protective agent and has important role
in the regulation of lung blood flows. The pri-
mary mechanism responsible for control pul-
monary flow can be arterial dilation. CGRP can
significantly weaken the pathological effects of
chronic pulmonary hypertension. Another pos-
sible hypothesis is that the regulation of lung
blood flows can be mediated by an up-regula-
tion of CGRP synthesis and release, or through
an enhanced sensitivity of the vascular to the
dilator effects of this peptide.
In the future, it is hoped that dissection of
the mechanisms that control CGRP production
and its actions will provide novel therapeutic
targets for hypertension and other pathologies.
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